Salmerón Febres Luis Miguel, Cuenca Manteca Jorge
Complejo Hospitalario Universitario de Granada, Unidad de Angiología y Cirugía Vascular, Granada, Spain.
Complejo Hospitalario Universitario de Granada, Unidad de Angiología y Cirugía Vascular, Granada, Spain.
Ann Vasc Surg. 2017 Jul;42:337-350. doi: 10.1016/j.avsg.2017.01.010. Epub 2017 Apr 6.
Anticoagulation is the treatment of choice in the management of venous thromboembolic disease. This approach is applied to reduce mortality and the risk of recurrences and associated complications. Standard therapy for non-oncologic patients has traditionally been based on parenteral anticoagulation followed by vitamin K antagonists. However, this approach has many limitations.
The aim of this manuscript was to critically review current evidence on the use of direct oral anticoagulants in the treatment of venous thromboembolic disease by analyzing the specific characteristics of each drug.
Direct oral anticoagulants have many advantages over standard therapy. While they are equally effective as standard therapy for reducing the possibility of recurrence of venous thromboembolic disease, they carry a lower risk of major bleeding.
Direct oral anticoagulants are an attractive alternative to standard therapy for the treatment of venous thromboembolism.
抗凝治疗是静脉血栓栓塞性疾病管理中的首选治疗方法。采用这种方法可降低死亡率、复发风险及相关并发症。传统上，非肿瘤患者的标准治疗基于肠外抗凝，随后使用维生素K拮抗剂。然而，这种方法有许多局限性。
本手稿的目的是通过分析每种药物的具体特性，批判性地回顾目前关于直接口服抗凝剂用于治疗静脉血栓栓塞性疾病的证据。
直接口服抗凝剂相对于标准治疗有许多优势。虽然它们在降低静脉血栓栓塞性疾病复发可能性方面与标准治疗同样有效，但大出血风险较低。
直接口服抗凝剂是治疗静脉血栓栓塞的标准治疗的一种有吸引力的替代方法。
